Sofosbuvir Medications

Sofosbuvir is a direct-acting antiviral that inhibits the NS5B polymerase of hepatitis C virus. It is used in regimens to treat chronic hepatitis C infection.

Sofosbuvir

$29.21 per pill

400mg

Select pack

About Sofosbuvir

Sofosbuvir is a nucleotide analog that revolutionized the treatment of chronic hepatitis C virus (HCV) infection. Classified as a direct-acting antiviral (DAA), it targets the NS5B RNA-dependent RNA polymerase, halting viral replication. Since its first approval in 2013 by the United States Food and Drug Administration and subsequent endorsement by the Therapeutic Goods Administration (TGA) in Australia, Sofosbuvir has become a cornerstone of interferon-free regimens. It appears in fixed-dose combinations such as Harvoni (sofosbuvir/ledipasvir) and Epclusa (sofosbuvir/velpatasvir), yet the molecule is also available as a stand-alone generic. Clinicians prescribe it for genotype-1, -2, -3, -4, -5, and -6 infections, often achieving cure rates above 95 % when used according to guideline-recommended durations. Off-label, Sofosbuvir has been explored in liver-transplant prophylaxis and in patients co-infected with HIV, reflecting its broad antiviral potency. For Australians seeking accessible treatment, the option to buy Sofosbuvir online offers a discreet pathway to a therapy that has transformed HCV management.

What is Sofosbuvir?

Sofosbuvir belongs to the class of direct-acting antivirals that inhibit the HCV NS5B polymerase, an enzyme essential for viral RNA synthesis. The TGA granted provisional registration in 2015 after the FDA’s initial approval in 2013, initially for genotype-1 infection and later expanding to all major genotypes. Its molecular structure mimics natural uridine, allowing incorporation into the viral RNA chain and resulting in termination of elongation. Brand-name products such as Harvoni, Sovaldi, and Epclusa contain Sofosbuvir, while generic tablets are manufactured under strict Good Manufacturing Practice (GMP) standards. These formulations are listed on the Australian Pharmaceutical Benefits Scheme (PBS) for eligible patients, ensuring broad accessibility. In addition to its primary indication for chronic HCV, Sofosbuvir’s pharmacology has prompted investigation in hepatitis B and certain RNA virus infections, although such uses remain experimental.

How Sofosbuvir Works

Mechanism of Action

Sofosbuvir is metabolized intracellularly to the active triphosphate GS-662. This metabolite competitively binds to the NS5-B polymerase’s active site, becoming incorporated into the nascent viral RNA strand. Once added, it lacks the 3′-hydroxyl group required for further elongation, effectively terminating the chain and preventing replication of the virus.

Therapeutic Effects

By halting RNA synthesis, Sofosbuvir reduces circulating viral load within days, allowing the immune system to clear infected hepatocytes. The resultant decline in HCV RNA correlates with rapid improvements in liver inflammation markers and, over weeks, restoration of liver function.

Onset and Duration

Clinical trials show that viral RNA becomes undetectable in > 90 % of patients after four weeks of therapy when combined with complementary agents. Treatment courses typically range from 8 to 24 weeks depending on genotype, presence of cirrhosis, and prior therapy. The drug’s half-life of approximately 27 hours supports once-daily dosing, and viral suppression persists after the final dose, leading to sustained virologic response (SVR) at 12 weeks post-treatment in the majority of cases.

Approved Uses and Applications

Approved Indications

Chronic hepatitis C infection (all genotypes) in adults ≥ 18 years, as defined by the TGA and endorsed by the Australian Clinical Guidelines for HCV.
Use in combination regimens: Sofosbuvir/ledipasvir (Harvoni) for genotype 1, 4, 5, 6; Sofosbuvir/velpatasvir (Epclusa) for pan-genotypic treatment; Sofosbuvir/voxilaprevir (Vosevi) for patients with previous DAA failure.

Off-Label Uses

Sofosbuvir has been examined as prophylaxis against HCV reinfection after liver transplantation and in HIV-coinfected cohorts where drug-drug interaction profiles are favorable. These applications lack formal regulatory approval in Australia but are documented in peer-reviewed studies such as those published in The Lancet and Journal of Hepatology.

Clinical Efficacy

Phase III trials (e.g., ASTRAL-1, ION-3) demonstrated SVR12 rates of 94-99 % across diverse patient populations. A pooled analysis in The New England Journal of Medicine reported cure rates exceeding 95 % when Sofosbuvir was paired with appropriate NS5A inhibitors, even among patients with compensated cirrhos - a benchmark that has reshaped HCV therapeutic goals.

Buying Sofosbuvir from Our Online Pharmacy

Why Choose Our Service

Accessing Sofosbuvir can be challenging through conventional channels due to supply constraints and PBS eligibility criteria. Our online pharmacy provides a streamlined, privacy-first solution that delivers certified medication directly to your doorstep, eliminating the need for in-person pharmacy visits.

Brand Names and Generic Options

Common brand products include Harvoni, Sovaldi, and Epclusa. Generic Sofosbuvir tablets, manufactured under WHO-prequalified facilities, are priced up to 55 % lower than branded equivalents, offering substantial savings without compromising quality.

Quality & Safety

We partner with licensed international pharmacies that operate under stringent regulatory oversight, ensuring each product meets TGA-recognized standards for purity and potency.

Pricing & Access

Competitive pricing structures, combined with a Lifetime 10 % discount on all reorders, make long-term therapy financially sustainable. Discounts are automatically applied at checkout, and bulk purchase options are available for eligible patients.

Discreet Delivery

Orders are packaged in neutral, tamper-evident envelopes. Express shipping delivers within ≈ 7 days, while standard delivery arrives in ≈ 3 weeks, both with full tracking.

Dosing, Formulations & Administration

Available Formulations

Sofosbuvir is supplied as 400 mg tablets for oral administration. Fixed-dose combinations (e.g., 400 mg/90 mg ledipasvir) are also available in tablet form.

Typical Dosing Ranges

For most genotype-1 infections, treatment initiates at 400 mg once daily for 12 weeks when combined with ledipasvir. Patients with compensated cirrhosis may extend therapy to 24 weeks, while those with prior DAA exposure may receive 12 weeks of Sofosbuvir/velpatasvir plus ribavirin. These examples illustrate standard practice; exact regimens must be individualized by a clinician.

Administration Guidelines

The tablet can be taken with or without food; a high-fat meal does not significantly affect absorption. If prescribed with ribavirin, timing should be staggered to reduce gastrointestinal discomfort. Renal impairment (eGFR < 30 mL/min) warrants dose adjustment or alternative therapy, and hepatic dysfunction may influence treatment duration.

A qualified healthcare professional must determine the precise dose, formulation, and length of therapy based on your medical history and laboratory results.

Safety Profile & Considerations

Common Side Effects

Fatigue (reported in ≈ 30 % of patients)
Headache (≈ 20 %)
Nausea (≈ 15 %)
Insomnia (≈ 10 %)

These events are typically mild to moderate and resolve without intervention.

Serious Adverse Events

Rare cases of severe hepatitis, myocardial infarction, and anaphylaxis have been documented. Immediate medical evaluation is required if chest pain, rapid heartbeat, or signs of an allergic reaction occur.

Contraindications

Severe hypersensitivity to Sofosbuvir or any component of the formulation.
Co-administration with strong NS5B polymerase inhibitors not approved for use with Sofosbuvir.

Drug Interactions

CYP3A4 inhibitors/inducers: While Sofosbuvir is not a major CYP substrate, concomitant use of potent inducers (e.g., rifampicin) can modestly lower exposure.
P-glycoprotein (P-gp) modulators: Co-administration with amiodarone may increase brady-related cardiac events; monitoring is advised.
Other DAAs: Combination with certain protease inhibitors (e.g., grazoprevir) requires dosage adjustment per prescribing information.

Special Populations

Pregnancy & Breastfeeding: Limited data exist; the FDA classifies Sofosbuvir as pregnancy category B. Counsel with an obstetrician before initiating therapy.
Elderly: Pharmacokinetics remain comparable; however, comorbidities and polypharmacy increase interaction risk.
Renal Impairment: In patients with eGFR < 30 mL/min, avoid regimens containing ribavirin; consider dose reduction if necessary.
Hepatic Dysfunction: For Child-Pugh C cirrhosis, Sofosbuvir-containing combinations are not recommended due to insufficient safety data.

Frequently Asked Questions

How does Sofosbuvir differ from other DAAs like ledipasvir? Sofosbuvir inhibits the NS5B polymerase, whereas ledipasvir targets the NS5A protein. Combining both agents blocks two distinct steps in the viral life cycle, enhancing cure rates.
What is the typical timeline for a patient to feel better after starting Sofosbuvir? Most patients notice a decline in fatigue and jaundice within 2-4 weeks, correlating with the rapid drop in viral load observed in clinical trials.
Can I take Sofosbuvir with alcohol? Alcohol does not directly affect Sofosbuvir’s metabolism, but excessive intake can worsen liver injury. Reduce or avoid alcohol to support optimal liver recovery.
What foods should I avoid while on Sofosbuvir therapy? No specific dietary restrictions are required. Maintaining a balanced diet supports overall health, but grapefruit juice does not interact with Sofosbuvir.
What should I do if I experience persistent nausea? Nausea is common; taking the tablet with a small meal or snack often helps. If symptoms continue beyond a week, contact your healthcare provider for possible anti-emetic options.
Is Sofosbuvir safe for patients with mild kidney disease? The drug is mainly cleared hepatically, and mild renal impairment generally does not necessitate dose changes. Nevertheless, lab monitoring is prudent.
How does Sofosbuvir compare to Harvoni in terms of effectiveness? Harvoni is a fixed-dose combination of Sofosbuvir and ledipasvir; the synergy yields cure rates of ≥ 95 % for genotype 1, mirroring the efficacy of separate components when used together.
Can Sofosbuvir be used after a liver transplant? Off-label studies suggest it can prevent HCV reinfection when started early post-transplant, but this strategy remains investigational and should be managed by a transplant hepatologist.
What monitoring is required during treatment? Baseline liver function tests, HCV RNA quantification, and periodic renal panels are standard. Some regimens also require hemoglobin monitoring if ribavirin is included.
What information should I provide my doctor when discussing Sofosbuvir?
- Full list of current medications, including over-the-counter and supplements
- Past hepatitis C treatment history and genotype, if known
- Presence of liver cirrhosis or other comorbidities
- Any history of kidney disease, cardiac conditions, or pregnancy

Disclaimer

The information provided about Sofosbuvir is for general knowledge only. It does not replace professional medical consultation or the official prescribing information for medications containing this ingredient. All treatment decisions, including dosing, formulation selection, and monitoring, should be made under the supervision of a qualified healthcare provider who can assess individual medical history, current medications, and specific health needs. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to medications containing Sofosbuvir for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication containing Sofosbuvir.